Why Protocol Complexity Keeps Increasing – and How to Fix It

Why It Matters

Reducing unnecessary data eases site workload, improves patient enrollment, and cuts development costs, directly affecting the speed and profitability of drug launches.

Key Takeaways

• Phase III protocols now capture ~6 million data points, rising 11% annually
• Study finds ~33% of trial procedures are non‑core or non‑essential
• ICH E6(R3) mandates fit‑for‑purpose data collection to cut excess
• Streamlined protocols reduce site burden, accelerate enrollment and lower costs
• Digital tools can flag redundant data early in design phase

Pulse Analysis

The relentless climb in protocol complexity reflects a paradox of modern drug development: scientific precision and digital capability enable richer data, but they also inflate trial size without proportional value. Phase III oncology and precision‑medicine studies now routinely collect millions of data points, driven by sophisticated biomarkers, multi‑regional regulatory nuances, and decentralized trial components. While these elements can sharpen efficacy signals, the cumulative burden often outweighs the insight, as evidenced by the TransCelerate‑Tufts finding that a third of procedures serve exploratory or “future‑use” purposes rather than core endpoints.

For investigative sites and participants, this overload translates into longer start‑up times, higher operational costs, and heightened risk of FDA non‑compliance. Sites must allocate more staff to manage data entry, while patients face extended visits, extra blood draws, and lengthy questionnaires that can deter enrollment—especially among under‑represented groups. Sponsors feel the ripple effect through diluted data quality and stretched budgets, jeopardizing the overall efficiency of the clinical pipeline. The recent ICH E6(R3) update directly addresses these pain points by urging a fit‑for‑purpose approach: collect only data essential to answer the primary scientific question and meet regulatory safety thresholds.

Implementing fit‑for‑purpose design starts with rigorous burden assessments, early site engagement, and leveraging analytics platforms that surface redundant data elements. By classifying each procedure against primary or key secondary endpoints, sponsors can prune non‑core activities, shortening trial timelines and reducing costs. Digital tools—such as protocol‑mapping software and AI‑driven data audits—enable real‑time adjustments when enrollment stalls or site feedback flags excess. The payoff is tangible: leaner protocols improve participant experience, boost data quality, and accelerate time‑to‑market, positioning forward‑thinking companies to win in an increasingly competitive and cost‑constrained therapeutic landscape.